Shares in Disa closed flat at 0.1 cents on Jan 8.

Digital Life Line Pte. Ltd., a subsidiary of DiSa Digital Safety Pte. Ltd., has signed a tri-party licensing agreement with the National University Hospital (Singapore) or NUH and the National University of Singapore (NUS) to commercialise the company’s mobile imaging device for anterior segment (MIDAS) on Jan 7. DiSa Digital Safety Pte. Ltd. is a wholly-owned subsidiary of Catalist-listed Disa Limited.

In its business update on Oct 25, 2024, Disa said that it was focusing on its eye screening devices, which included the development of MIDAS, which could detect eye pathologies. MIDAS, a portable smartphone slit lamp imaging device, is registered with the Health Science Authority of Singapore (HSA) and is designed for cataract screening in primary care settings. The device is meant to be used by patients, nurses, primary care physicians such as general practitioners, polyclinic doctors and emergency physicians.

According to Disa, chronic eye conditions such as cataracts are becoming increasingly common among Singapore’s rapidly ageing population. Referring to a study conducted by the Singapore National Eye Centre, over 80% of people aged 60 and above in Singapore have some form of cataract.

“We are honoured to be given another opportunity to work with NUH and NUS to commercialise MIDAS in Singapore and hopefully, regionally in the near future,” says Eddie Chng, managing director and CEO of Disa and Digital Life Line.

“With our portable artificial intelligence-powered cataract screening device, we are bringing advanced eye care directly to the community,” he adds. “Our in-house developed artificial intelligence (AI)-algorithms can eliminate the need for trained staff to identify the best image and process the cataract grading parameters within 10 seconds. By harnessing intelligent triaging based on an established cataract grading system, we aim to ensure that each referral is both timely and accurate.”

Shares in Disa closed flat at 0.1 cents on Jan 8.